1. Home
  2. OMER vs UTL Comparison

OMER vs UTL Comparison

Compare OMER & UTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Omeros Corporation

OMER

Omeros Corporation

HOLD

Current Price

$17.80

Market Cap

844.6M

Sector

Health Care

ML Signal

HOLD

Logo UNITIL Corporation

UTL

UNITIL Corporation

HOLD

Current Price

$52.05

Market Cap

906.9M

Sector

Utilities

ML Signal

HOLD

Company Overview

Basic Information
Metric
OMER
UTL
Founded
1994
1984
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Power Generation
Sector
Health Care
Utilities
Exchange
Nasdaq
Nasdaq
Market Cap
844.6M
906.9M
IPO Year
2008
1995

Fundamental Metrics

Financial Performance
Metric
OMER
UTL
Price
$17.80
$52.05
Analyst Decision
Strong Buy
Buy
Analyst Count
5
2
Target Price
$32.50
$56.50
AVG Volume (30 Days)
1.5M
96.9K
Earning Date
05-14-2026
05-04-2026
Dividend Yield
N/A
3.65%
EPS Growth
98.15
1.37
EPS
0.77
2.11
Revenue
$29,868,000.00
$536,000,000.00
Revenue This Year
N/A
$5.43
Revenue Next Year
$233.22
$4.22
P/E Ratio
$23.96
$25.19
Revenue Growth
N/A
8.33
52 Week Low
$4.06
$45.17
52 Week High
$19.65
$57.26

Technical Indicators

Market Signals
Indicator
OMER
UTL
Relative Strength Index (RSI) 54.24 39.24
Support Level $10.82 $52.10
Resistance Level $19.60 $52.19
Average True Range (ATR) 0.79 1.02
MACD -0.38 -0.12
Stochastic Oscillator 45.57 13.46

Price Performance

Historical Comparison
OMER
UTL

About OMER Omeros Corporation

Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.

About UTL UNITIL Corporation

Unitil Corp through its subsidiaries engages in the distribution of electricity and natural gas in its service territories in the states of New Hampshire, Massachusetts and Maine. Its natural gas operations include gas distribution utility operations and interstate gas transmission pipeline operations. It also engages in interstate natural gas transmission pipeline company, operating approximately 85 miles of underground gas transmission pipeline located in Maine and New Hampshire. The company's segments include Electric and Gas.

Share on Social Networks: